Department of Medical Oncology, OncoProteomics Laboratory, VU University Medical Center, De Boelelaan 1117, 1081 HV Amsterdam, The Netherlands.
Anal Bioanal Chem. 2010 Aug;397(8):3163-71. doi: 10.1007/s00216-010-3784-7. Epub 2010 Jun 8.
Kinases are key enzymes involved in deregulated signal transduction associated with cancer development and progression. The advent of personalized medicine drives the development of new diagnostic tools for patient stratification and therapy selection Ginsburg and Willard (Transl Res 154:277-287, 2009). Since deregulation of kinase-mediated signal transduction is implied in tumorigenesis, the analysis of all kinases (the kinome) active in a particular tumor may yield tumor-specific information on aberrant cell signalling pathways. Tumor tissue kinase activity profiles may correlate with response to therapy and therefore may be used for future therapy selection. In this Trend paper we describe peptide array and mass spectrometry-based technologies and new developments for kinome profiling, and we present an outlook towards future implementation of therapy selection based on kinome profiling in clinical practice.
激酶是与癌症发生和发展相关的失调信号转导中涉及的关键酶。个性化医疗的出现推动了新的诊断工具的发展,用于患者分层和治疗选择。金斯堡和威拉德(Transl Res 154:277-287, 2009)。由于激酶介导的信号转导失调暗示了肿瘤发生,因此分析特定肿瘤中所有活跃的激酶(激酶组)可能会提供关于异常细胞信号通路的肿瘤特异性信息。肿瘤组织的激酶活性谱可能与治疗反应相关,因此可用于未来的治疗选择。在这篇趋势论文中,我们描述了基于肽阵列和质谱的技术以及激酶组分析的新进展,并对未来在临床实践中基于激酶组分析进行治疗选择的实施进行了展望。